BioVie, Inc. (BIVI)
Total Valuation
BioVie has a market cap or net worth of $64.21 million. The enterprise value is $51.45 million.
Market Cap | 64.21M |
Enterprise Value | 51.45M |
Important Dates
Earnings Date | n/a |
Ex-Dividend Date | n/a |
Share Statistics
BioVie has 24.98 million shares outstanding. The number of shares has increased by 79.48% in one year.
Shares Outstanding | 24.98M |
Shares Change (YoY) | +79.48% |
Shares Change (QoQ) | +0.09% |
Owned by Insiders (%) | 79.74% |
Owned by Institutions (%) | 6.28% |
Float | 5.13M |
Valuation Ratios
PE Ratio | n/a |
Forward PE | n/a |
PS Ratio | n/a |
PB Ratio | 6.45 |
P/FCF Ratio | n/a |
PEG Ratio | n/a |
Enterprise Valuation
EV / Earnings | n/a |
EV / Sales | n/a |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 5.74, with a Debt / Equity ratio of 1.18.
Current Ratio | 5.74 |
Quick Ratio | 5.68 |
Debt / Equity | 1.18 |
Debt / EBITDA | n/a |
Debt / FCF | n/a |
Financial Efficiency
Return on equity (ROE) is -1,165.80%, which is considered low. The company has a ROIC of -4,671.60%.
Return on Equity (ROE) | -1,165.80% |
Return on Assets (ROA) | -694.80% |
Return on Capital (ROIC) | -4,671.60% |
Revenue Per Employee | n/a |
Profits Per Employee | -$24.92M |
Employee Count | 6 |
Asset Turnover | n/a |
Inventory Turnover | n/a |
Taxes
Income Tax | n/a |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -82.54% in the last 52 weeks. The beta is 2.26, so BioVie's price volatility has been higher than the market average.
Beta (1Y) | 2.26 |
52-Week Price Change | -82.54% |
50-Day Moving Average | 3.51 |
200-Day Moving Average | 4.18 |
Average Volume (30 Days) | 38,431 |
Short Selling Information
The latest short interest is 121,731, so 0.49% of the outstanding shares have been sold short.
Short Interest | 121,731 |
Short % of Shares Out | 0.49% |
Short % of Float | 2.37% |
Short Ratio (days to cover) | 2.58 |
Income Statement
Revenue | n/a |
Gross Profit | n/a |
Operating Income | -149.56M |
Net Income | -149.53M |
EBITDA | -148.06M |
EBIT | -148.29M |
Earnings Per Share (EPS) | -$6.69 |
Balance Sheet
The company has $24.51 million in cash and $11.75 million in debt, giving a net cash position of $12.75 million or $0.51 per share.
Cash & Cash Equivalents | 24.51M |
Total Debt | 11.75M |
Net Cash | 12.75M |
Net Cash Per Share | $0.51 |
Book Value | 9.95M |
Book Value Per Share | 0.40 |
Working Capital | 20.47M |
Cash Flow
Operating Cash Flow | -20.13M |
Capital Expenditures | n/a |
Free Cash Flow | -20.13M |
FCF Per Share | n/a |
Margins
Gross Margin | n/a |
Operating Margin | n/a |
Pretax Margin | n/a |
Profit Margin | n/a |
EBITDA Margin | n/a |
EBIT Margin | n/a |
FCF Margin | n/a |
Dividends & Yields
BioVie does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Earnings Yield | -232.88% |
FCF Yield | -31.36% |
Dividend Growth (YoY) | n/a |
Payout Ratio | n/a |
Buyback Yield | -79.48% |
Shareholder Yield | -79.48% |
Analyst Forecast
The average price target for BioVie is $13.94, which is 442.41% higher than the current price. The consensus rating is "Buy".
Price Target | $13.94 |
Price Target Difference | 442.41% |
Analyst Consensus | Buy |
Analyst Count | 9 |
Stock Splits
The last stock split was on November 22, 2019. It was a reverse split with a ratio of 1:125.
Last Split Date | Nov 22, 2019 |
Split Type | Reverse |
Split Ratio | 1:125 |